Gene Therapy Delivery Methods – Viral & Non-viral Approach & Risk Mitigation Efforts

  • Public Equity
  • Healthcare
  • North America


Director at a biomedical research organisation and medical school


  • Notable driving trends and developments within gene therapy, including overall industry growth-inducing factors
  • Overview of clinical risks and uncertainties associated with gene therapy delivery, highlighting a field emphasis on risk mitigation and unwanted immune responses associated with viral vs non-viral delivery methods
  • Innovation and technological advancement in gene therapy delivery, highlighting higher-quality improved capsids
  • Therapeutic outlook and best-suited delivery methods for indications across CNS (central nervous system), oncology and cardiovascular disease
  • 2023 industry outlook and future potential


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited